Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies

ABSTRACT: Herein, we assembled a cohort composed of 254 CRC patients, including discovery cohort (N = 124) and validation cohort (N = 130), which received either chemotherapy (mainly FOLFOX therapy), chemoradiotherapy (mainly FOLFOX combined with radiotherapy), or targeted combination therapy (mainly FOLFOX combined with cetuximab).

ORGANISM(S): Homo Sapiens

SUBMITTER: Chen Ding

PROVIDER: PXD046566 | iProX | Mon Oct 30 00:00:00 GMT 2023

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Mkango2019 - Dynamics of Breast Cancer under DifferentRates of Chemoradiotherapy

Project description:Dynamics of Breast Cancer under Different Rates of Chemoradiotherapy. Mkango SB1, Shaban N1, Mureithi E1, Ngoma T2. Author information 1 Department of Mathematics, University of Dar es Salaam, P.O. Box 35062, Dar es Salaam, Tanzania. 2 Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, P.O. Box 65000, Dar es Salaam, Tanzania. Abstract A type of cancer which originates from the breast tissue is referred to as breast cancer. Globally, it is the most common cause of death in women. Treatments such as radiotherapy, chemotherapy, hormone therapy, immunotherapy, and gene therapy are the main strategies in the fight against breast cancer. The present study aims at investigating the effects of the combined radiotherapy and chemotherapy as a way to treat breast cancer, and different treatment approaches are incorporated into the model. Also, the model is fitted to data on patients with breast cancer in Tanzania. We determine new treatment strategies, and finally, we show that when sufficient amount of chemotherapy and radiotherapy with a low decay rate is used, the drug will be significantly more effective in combating the disease while health cells remain above the threshold. Copyright © 2019 Sara B. Mkango et al.

2020-01-20 | MODEL1912120005 | BioModels

Lactobacillus enrichment and its association with gene expression in ER negative breast tumor tissue

Project description:ER+ patients are treated with hormone inhibitors combined with radiotherapy and chemotherapy, while ER- patients especially triple negative breast cancer, there are few treatment options other than radiotherapy and chemotherapy. However, there are no reports on the analysis of microbiome and its association with cancer development.

2021-10-08 | GSE185439 | GEO

Next-generation sequencing is useful for quantitative analysis of the transcriptome of HMME-RGD@C3F8 NBs under low-frequency ultrasound irradiation combined with Elesclomol-Cu treated and untreated HCC cells

Project description:Hepatocellular carcinoma has a hidden onset and is often found at an advanced stage clinically. Moreover, because it is insensitive to radiotherapy and chemotherapy, its treatment is often difficult. In this study, we constructed nanobubbles loaded with sonosensitizer HMME and tumor-targeting peptide RGD (HMME-RGD@C3F8 NBs) combined with cuproptosis inducer Elesclomol-Cu to achieve sonodynamic/cuproptosis combined therapy for hepatocellular carcinoma (HCC). Furthermore, to explore the mechanism of the enhanced anti-tumor efficacy of synergistic sonodynamic/cuproptosis therapy, RNA sequencing was performed.

2025-08-01 | GSE274917 | GEO

The effects of nintedanib combined with radiation on gene transcription in the MC38 cell line

Project description:Nintedanib, a small molecule tyrosine kinase inhibitor, has been approved for patients with NSCLC who progressed following first-line chemotherapy. However, there are relatively few related studies on the treatment strategy of nintedanib combined with radiotherapy. This study aims to explore the effectiveness and mechanism of nintedanib combined with radiotherapy in both in vivo and in vitro experiments.

2025-05-31 | GSE297011 | GEO

DNA Methylation Markers Predict Recurrence-free Interval in Triple-Negative Breast Cancer.

Project description:We lack tools to risk-stratify triple-negative breast cancer (TNBC). Our goal was to develop molecular tools to predict disease recurrence. Methylation array analysis was performed on 110 samples treated by locoregional therapy obtained from Institutional cohorts. Discovered marker sets were then tested by Kaplan Meier analyses in a prospectively collected TNBC cohort of 49 samples from the no chemotherapy arms of IBCSG trials VIII and IX, and by logistic regression in a chemotherapy-treated cohort of 121 TNBCs from combined IBCSG trials and Institutional repositories. High methylation was associated with shorter recurrence-free interval in the no chemotherapy arm of the IBCSG studies, as well as in the chemotherapy-treated patients within the combined Institutional and IBCSG chemotherapy cohorts (100 marker panel, P=0.002; 30 marker panel, P=0.05). Chromosome 19 sites were enriched among these loci. In conclusion, our hypermethylation signatures identify increased recurrence risk independent of whether patients receive chemotherapy.

2019-12-05 | GSE141441 | GEO

Neoadjuvant anlotinib combined with PD-1 blockade therapy remodeling the microenvironment in advanced non-small cell lung cancer

Project description:Neoadjuvant anlotinib combined with PD-1 blockade therapy can prolong the survival of patients, but the underlying mechanisms for the failure of patients to benefit from combination therapy remain to be explored. To explore the mechanism of drug resistance and predict patient response, we performed scRNA-seq from 6 NSCLC patients, including 3 post-treatment patients with major pathological response (MPR), and 3 Non-MPR patients to observe and analyze the dynamic changes of immune cells, stromal cells and cancer cells from the NSCLC patients who received neoadjuvant anlotinib combined with PD-1 blockade therapy and verified in an independent cohort.

2025-03-31 | GSE291670 | GEO

Gene expression and mutation profiles in advanced-stage epithelial ovarian cancer (EOC)

Project description:Purpose: This open-label, investigator-initiated, phase II study was conducted to evaluate the safety, survival and neoadjuvant outcomes of NAC combined with dual immune checkpoint inhibitors in advanced-stage EOC. Patients and methods: Between June 2019 and July 2021, 45 patients with unresectable stage III-IV EOC were enrolled. The patients received three cycles of NAC combined with durvalumab and tremelimumab. All patients underwent interval debulking surgery and received three cycles of durvalumab and adjuvant chemotherapy, followed by 12 cycles of durvalumab as maintenance therapy. The primary endpoint was the 12-month progression-free survival (PFS) rate; the secondary endpoints were the objective response rate (ORR) after NAC, a chemotherapy response score (CRS), pathologic complete response (pCR), overall survival (OS), and safety. The pre-planned exploratory analyses assessed the lymphocyte infiltration, PD-L1 expression, and genomic profiles of pre-treatment tumors.

2025-01-15 | GSE284400 | GEO

The effect of hyperthermia on nasopharyngeal carcinoma cells

Project description:Hyperthermia has shown unique advantages in tumor treatment as an anti-cancer treatment method, which combined with radiotherapy and/or chemotherapy reduces the side effects. However, its specific mechanism is unknown.

2022-06-01 | GSE189578 | GEO

A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer

Project description:This is a Phase II trial to study the safety and efficacy of IMMU-130. IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for colorectal cancer. Antibodies are proteins normally made by the immune system. They bind to substances that don’t belong in the body to prevent harm to the body. The antibody in this study was designed to bind to a marker located on colorectal cancer tumors. The antibody was originally made from mouse proteins, but was changed in the laboratory to be more like human antibodies. This study will investigate how IMMU-130 acts for the treatment of colorectal cancer. The study is mainly being done to see if IMMU-130 is safe and effective.

| 2149536 | ecrin-mdr-crc

Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer

Project description:This is a Phase I trial to study the safety of IMMU-130. IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for colorectal cancer. Antibodies are proteins normally made by the immune system. They bind to substances that don’t belong in the body to prevent harm to the body. The antibody in this study was designed to bind to a marker located on colorectal cancer tumors. The antibody was originally made from mouse proteins, but was changed in the laboratory to be more like human antibodies. This study will investigate how IMMU-130 acts for the treatment of colorectal cancer. The study is mainly being done to see if IMMU-130 is safe.

| 2100352 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data